卷曲霉素联合莫西沙星治疗耐多药肺结核的应用价值  

Application value of capreomycin combined with moxifloxacin in the treatment of multi-drug resistant pulmonary tuberculosis

作　　者：林峰[1] LIN Feng(Affiliated Zhongshan Hospital of Dalian University,Dalian 116000,China)

机构地区：[1]大连大学附属中山医院

出　　处：《中国现代药物应用》2019年第21期14-16,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨卷曲霉素联合莫西沙星治疗耐多药肺结核的临床疗效。方法78例耐多药肺结核患者,按照治疗方式不同分为观察组与对照组,每组39例。所有患者均给予常规治疗,对照组给予莫西沙星治疗,观察组给予卷曲霉素联合莫西沙星治疗。观察比较两组患者病灶吸收情况、病灶空洞闭合情况、治疗前后炎性因子水平及不良反应发生情况。结果观察组病灶吸收率84.6%明显高于对照组的64.1%,差异具有统计学意义(P<0.05)。观察组病灶空洞闭合率87.2%高于对照组的66.7%,差异具有统计学意义(P<0.05)。治疗后,观察组患者白细胞介素-1(IL-1)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平分别为(17.4±2.8)、(147.3±12.3)、(84.3±11.5)ng/ml,均低于对照组的(23.7±4.1)、(179.3±15.7)、(113.7±12.4)ng/ml,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率15.4%明显低于对照组的35.9%,差异具有统计学意义(P<0.05)。结论对耐多药肺结核患者实施卷曲霉素联合莫西沙星治疗,疗效显著,值得临床推广。Objective To discuss the clinical efficacy of capreomycin combined with moxifloxacin in the treatment of multi-drug resistant pulmonary tuberculosis. Methods A total of 78 patients with multi-drug resistant pulmonary tuberculosis were divided into observation group and control group according to different treatment methods, with 39 cases in each group. All patients received conventional therapy, and the control group was treated with moxifloxacin. The observation group was treated with capreomycin and moxifloxacin. Observation and comparison were made on absorption of lesions, closure of cavity, levels of inflammatory factors before and after treatment, and occurrence of adverse reactions between the two groups. Results The absorption rate of lesions 84.6% in the observation group was higher than 64.1% in the control group, and the difference was statistically significant(P<0.05). The closure of cavity 87.2% in the observation group was higher than 66.7% in the control group, and the difference was statistically significant(P<0.05). After treatment, the levels of interleukin-1(IL-1), interleukin-6(IL-6), tumor necrosis factor-α(TNF-α) were(17.4±2.8),(147.3±12.3) and(84.3±11.5) ng/ml respectively in the observation group, which was lower than(23.7±4.1),(179.3±15.7) and(113.7±12.4) ng/ml in the control group, and their difference was statistically significant(P<0.05). The incidence of adverse reactions 15.4% in the observation group was obviously lower than 35.9% in the control group, and the difference was statistically significant(P<0.05). Conclusion Capreomycin combined with moxifloxacin has significant efficacy on patients with multi-drug resistant pulmonary tuberculosis, and it is worthy of clinical promotion.

关 键 词：卷曲霉素 莫西沙星 耐多药肺结核 疗效 

分 类 号：R52[医药卫生—内科学]